Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Cancer Registry (NCR)

Definition A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives - To measure cancer incidence
- To describe cancer by time, place, persons and disease
- To provide a national database for further epidemiological research
Case definition Target cases are:
- Incident cases by year of diagnosis
- Malignant tumors confirmed by histopathology and/or hematology findings
- Cancers of all sites
Sources of data Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting).
1) The capture system: 
The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms:
- Directly from their clinic; or
- Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients
2) The recapture system: 
The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3).
The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor.
The structure is C##.# M####/##, where:
- C##.# specifies the primary site
- M#### specifies the histology
- /## specifies the behavior and the grade of the tumor
Reporting form NCR reporting form
    ...
    145
    ...
ATC Name B/G Ingredients Dosage Form Price
J01DD04 TRIAXONE G Ceftriaxone (sodium) - 1g, Lidocaine - 1% 1g Injectable powder for solution+diluent 438,093 L.L
J01XX01 FOSFOLAG G Fosfomycine (trométamol) - 3g 3g Granules for solution 399,121 L.L
L01BA04 SUKUBA G Pemetrexed (disodium) - 500mg 500mg Injectable lyophilised powder 34,786,563 L.L
M01AH01 NORMOCOXIB G Celecoxib - 200mg 200mg Capsule, hard 798,242 L.L
N02BE01 DOLOPAN G Paracetamol - 500mg 500mg Tablet, film coated 380,115 L.L
N04BA02 CARLEVO G Levodopa - 100mg, Carbidopa - 25mg Tablet 2,431,715 L.L
N06AB10 PRYLEX 20 G Escitalopram (oxalate) - 20mg 20mg Tablet, film coated 972,686 L.L
R03AK06 PROPIONATE DE FLUTICASONE/ SALMETEROL ARROW G Salmeterol - 50mcg/dose, Fluticasone propionate - 250mcg/dose Inhalation powder 1,980,824 L.L
R06AX27 RINA 5 G Desloratadine - 5mg 0.5mg/ml Tablet, film coated 134,384 L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 355,798 L.L
A10BA02 DIAPHAGE G Metformin HCl - 1g 1g Tablet, extended release 150,510 L.L
A15 DESARROL G Cyproheptadine HCl - 0.2mg/ml, L-Arginine L-Aspartate - 25mg/ml, L-Carnitine - 50mg/ml Solution 1,007,882 L.L
B05XA03 SOLUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 203,405 L.L
C07AB12 BLOVEK G Nebivolol HCl - 5mg Tablet 511,940 L.L
G01AF05 ECOGYN G Econazole nitrate - 150mg 150mg Pessary 447,948 L.L
H02AB02 DEXAMETHASONE G Dexamethasone - 0.5mg/5ml 0.5mg/5ml Elixir 119,026 L.L
J01DD04 TRIAXONE G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 4,542,188 L.L
M01AH01 REVCOX G Celecoxib - 200mg 200mg Capsule 506,629 L.L
N02BE01 DOLOPAN G Paracetamol - 500mg 500mg Tablet, film coated 317,403 L.L
N04BA03 COMBIPAR G Levodopa - 100mg, Carbidopa - 25mg, Entacapone - 200mg Tablet, film coated 1,249,926 L.L
N06AB10 ZELAX 20 G Escitalopram (oxalate) - 20mg 20mg Caplet 1,544,075 L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 2,557,140 L.L
A10BA02 METFORKEY G Metformin HCl - 1.000mg 1.000mg Tablet, extended release 374,932 L.L
A15A DYNAMOGEN G Arginine Aspartate - 1g/10ml, Glutodine (Cyproheptadine ?-ketoglutarate) - 3mg/10ml Solution 1,019,976 L.L
B05XA03 SOLUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 179,272 L.L
C07AB12 NEBIVOLOL BIOGARAN G Nebivolol HCl - 5mg 5mg Tablet, scored 529,474 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 40mg, Hydrochlorothiazide - 25mg Tablet, film coated 653,107 L.L
G01AF05 ECONAZ G Econazole nitrate - 150mg 150mg Ovule 415,951 L.L
H02AB02 DEXAMED G Dexamethasone - 8mg/2ml 8mg/2ml Injectable solution 3,547,744 L.L
J01DD04 VERACOL G Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 454,219 L.L
    ...
    145
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025